AI assistant
Anika Therapeutics, Inc. — Director's Dealing 2021
Mar 1, 2021
33997_dirs_2021-03-01_95911245-9f5b-46ec-aee0-db02b8cabf70.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Anika Therapeutics, Inc. (ANIK)
CIK: 0000898437
Period of Report: 2021-02-25
Reporting Person: Loerop James (EVP Business Development)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-25 | Common Stock | M | 1567 | — | Acquired | 3323 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-25 | Restricted Stock Unit | $0.00 | M | 1567 | Disposed | Common Stock (1567) | Direct |
Footnotes
F1: Reflects the first vesting installment of deferred stock units ("DSUs") granted on February 25, 2020.
F2: The settlement of these DSUs shall be deferred until the grantee incurs a "separation of service" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in a single-lump sum within 60 days of the anniversary of such event.
F3: Each DSU represents the contingent right to receive one share of the Company's common stock. The DSUs vest in three equal annual installments beginning on February 25, 2021.